Literature DB >> 23733213

Endobiliary stent: marker for patient alignment in image-guided radiotherapy in pancreatic and periampullary cancers.

Pragya Shukla1, Reena Engineer, Supriya Chopra, Shyam Kishore Shrivastava.   

Abstract

PURPOSE: The aim of this study was to analyse the possibility of using stent in pretreatment megavoltage computed tomography (MVCT) images with respect to that on planning kilovoltage computed tomography as tumour surrogate during matching for daily registration in cases of pancreatic and periampullary cancer treated on a TomoTherapy Hi-Art system.
METHODS: Planning CT and pretreatment MVCT of the first and then after every three fractions were transferred to a FocalSim workstation for ten patients. Planning CT of each patient was independently fused with each of the seven MVCT images of that patient. The stent was contoured on all of the eight images for each patient. The difference between the three co-ordinates of centre of mass (CM) of the stent on the planning CT and seven MVCT images was found. The difference between CM of the liver and stents on the planning CT as well as on the MVCT for all seven fractions was also calculated. The mean of these differences across all patients was calculated and analysed.
RESULTS: The mean difference in planning and MVCT CMs for stents in the X, Y and Z directions was 0.13 cm (±0.4), 0.16 cm (±2.2) and 0.35 cm (±0.7), respectively. Average difference between CM of the liver and stent on the planning CT in the X, Y and Z directions was found to be 1.832 cm (±1.64), 5.34 cm (±1.33) and 0.54 cm (±0.26), respectively. Average difference between CM of the liver and CM of stent on the MVCT for that day in the X, Y and Z directions was found to be 1.93 cm (±1.5), 4.6 cm (±1.03) and 0.654 cm (±0.35), respectively.
CONCLUSIONS: Endobiliary stents are stable tumour localisation surrogates and can be used to correct for interfraction target motion.

Entities:  

Mesh:

Year:  2013        PMID: 23733213     DOI: 10.1007/s12029-013-9508-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  10 in total

1.  Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT).

Authors:  Kei Kitamura; Hiroki Shirato; Shinichi Shimizu; Nobuo Shinohara; Toru Harabayashi; Tadashi Shimizu; Yoshihisa Kodama; Hideho Endo; Rikiya Onimaru; Seiko Nishioka; Hidefumi Aoyama; Kazuhiko Tsuchiya; Kazuo Miyasaka
Journal:  Radiother Oncol       Date:  2002-03       Impact factor: 6.280

2.  A comparison of soft-tissue implanted markers and bony anatomy alignments for image-guided treatments of head-and-neck cancers.

Authors:  Omar A Zeidan; Adam J Huddleston; Choonik Lee; Katja M Langen; Patrick A Kupelian; Sanford L Meeks; Rafael R Manon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-07       Impact factor: 7.038

3.  EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy.

Authors:  Walter G Park; Brian M Yan; Devin Schellenberg; Jeff Kim; Daniel T Chang; Albert Koong; Cheryl Patalano; Jacques Van Dam
Journal:  Gastrointest Endosc       Date:  2010-03       Impact factor: 9.427

4.  The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: a case series.

Authors:  S Varadarajulu; J M Trevino; S Shen; R Jacob
Journal:  Endoscopy       Date:  2010-03-15       Impact factor: 10.093

5.  Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions.

Authors:  Aaron C Spalding; Kyung-Wook Jee; Karen Vineberg; Marla Jablonowski; Benedick A Fraass; Charlie C Pan; Theodore S Lawrence; Randall K Ten Haken; Edgar Ben-Josef
Journal:  Med Phys       Date:  2007-02       Impact factor: 4.071

6.  Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?

Authors:  Reena Engineer; Tabassum Wadasadawala; Shaesta Mehta; Umesh Mahantshetty; Nilendu Purandare; Venkatesh Rangarajan; Shyam Kishore Shrivastava
Journal:  J Gastrointest Cancer       Date:  2011-12

7.  Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer.

Authors:  Barbara Bussels; Laurence Goethals; Michel Feron; Didier Bielen; Steven Dymarkowski; Paul Suetens; Karin Haustermans
Journal:  Radiother Oncol       Date:  2003-07       Impact factor: 6.280

8.  Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.

Authors:  Lisa Hazard; Jonathan D Tward; Aniko Szabo; Dennis C Shrieve
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

9.  Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.

Authors:  C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

10.  Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

Authors:  H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer
Journal:  Eur J Surg Oncol       Date:  2008-01-10       Impact factor: 4.424

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.